The announcement of distributing shares of HOPE Therapeutics and royalty rights on Ketamine sales is a positive development for NRx Pharmaceuticals. It directly benefits existing shareholders by providing them with additional assets and potential income streams, which is likely to be viewed positively by the market. This kind of equity action typically results in a positive short-term impact on the company's stock price as it reflects growth and value addition to the shareholders.